Literature DB >> 20624947

Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype.

Norman Yeh1, Nicole L Glosson, Nan Wang, Lynette Guindon, Carl McKinley, Hiromasa Hamada, Qingsheng Li, Richard W Dutton, Protul Shrikant, Baohua Zhou, Randy R Brutkiewicz, Janice S Blum, Mark H Kaplan.   

Abstract

CD8 T cells can acquire cytokine-secreting phenotypes paralleling cytokine production from Th cells. IL-17-secreting CD8 T cells, termed Tc17 cells, were shown to promote inflammation and mediate immunity to influenza. However, most reports observed a lack of cytotoxic activity by Tc17 cells. In this study, we explored the anti-viral activity of Tc17 cells using a vaccinia virus (VV) infection model. Tc17 cells expanded during VV infection, and TCR transgenic Tc17 cells were capable of clearing recombinant VV infection. In vivo, adoptively transferred Tc17 cells lost the IL-17-secreting phenotype, even in the absence of stimulation, but they did not acquire IFN-gamma-secreting potential unless stimulated with a virus-encoded Ag. However, examination of cells following infection demonstrated that these cells acquired cytotoxic potential in vivo, even in the absence of IFN-gamma. Cytotoxic potential correlated with Fasl expression, and the cytotoxic activity of postinfection Tc17 cells was partially blocked by the addition of anti-FasL. Thus, Tc17 cells mediate VV clearance through expression of specific molecules associated with cytotoxicity but independent of an acquired Tc1 phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624947      PMCID: PMC2916954          DOI: 10.4049/jimmunol.1000818

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

2.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.

Authors:  Andrew M Intlekofer; Naofumi Takemoto; E John Wherry; Sarah A Longworth; John T Northrup; Vikram R Palanivel; Alan C Mullen; Christopher R Gasink; Susan M Kaech; Joseph D Miller; Laurent Gapin; Kenneth Ryan; Andreas P Russ; Tullia Lindsten; Jordan S Orange; Ananda W Goldrath; Rafi Ahmed; Steven L Reiner
Journal:  Nat Immunol       Date:  2005-11-06       Impact factor: 25.606

3.  Disruption of MHC class II-restricted antigen presentation by vaccinia virus.

Authors:  Ping Li; Nan Wang; Delu Zhou; Christina S K Yee; Cheong-Hee Chang; Randy R Brutkiewicz; Janice S Blum
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

4.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

5.  Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice.

Authors:  M H Kaplan; Y L Sun; T Hoey; M J Grusby
Journal:  Nature       Date:  1996-07-11       Impact factor: 49.962

6.  Interleukin 17 modulates the immune response to vaccinia virus infection.

Authors:  Andriani C Patera; Lesley Pesnicak; John Bertin; Jeffrey I Cohen
Journal:  Virology       Date:  2002-07-20       Impact factor: 3.616

7.  Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.

Authors:  Michiko K Oyoshi; Abdallah Elkhal; Lalit Kumar; Jordan E Scott; Suresh Koduru; Rui He; Donald Y M Leung; Michael D Howell; Hans C Oettgen; George F Murphy; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

8.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression.

Authors:  R R Brutkiewicz; S J Klaus; R M Welsh
Journal:  Nat Immun       Date:  1992 Jul-Aug

10.  Tc17 CD8 T cells: functional plasticity and subset diversity.

Authors:  Hung-Rong Yen; Timothy J Harris; Satoshi Wada; Joseph F Grosso; Derese Getnet; Monica V Goldberg; Kai-Li Liang; Tullia C Bruno; Kristin J Pyle; Siaw-Li Chan; Robert A Anders; Cornelia L Trimble; Adam J Adler; Tzou-Yien Lin; Drew M Pardoll; Ching-Tai Huang; Charles G Drake
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

View more
  27 in total

1.  IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.

Authors:  Kai Sun; Hui-Hua Hsiao; Minghui Li; Erik Ames; Myriam Bouchlaka; Lisbeth A Welniak; Takeshi Hagino; Jared Jagdeo; Chien-Chun Pai; Mingyi Chen; Bruce R Blazar; Mehrdad Abedi; William J Murphy
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

2.  Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model.

Authors:  Antara Banerjee; Parna Bhattacharya; Pradeep K Dagur; Subir Karmakar; Nevien Ismail; Amritanshu B Joshi; Adovi D Akue; Mark KuKuruga; John Philip McCoy; Ranadhir Dey; Hira L Nakhasi
Journal:  J Immunol       Date:  2017-11-29       Impact factor: 5.422

3.  IL-17A expression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunization.

Authors:  Jayashree Ravichandran; Ronald J Jackson; Shubhanshi Trivedi; Charani Ranasinghe
Journal:  J Interferon Cytokine Res       Date:  2014-12-10       Impact factor: 2.607

4.  Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Gregory A Poland; Inna G Ovsyannikova; Ann L Oberg; Yan W Asmann; Diane E Grill; Robert A Vierkant; Robert M Jacobson
Journal:  Vaccine       Date:  2016-05-11       Impact factor: 3.641

5.  Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.

Authors:  María F Pascutti; Ana M Rodríguez; Juliana Falivene; Luis Giavedoni; Ingo Drexler; M Magdalena Gherardi
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

6.  Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques.

Authors:  William D Cornwell; Mark G Lewis; Xiaoxuan Fan; Jay Rappaport; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

Review 7.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

8.  Pulmonary immune responses to Aspergillus fumigatus in an immunocompetent mouse model of repeated exposures.

Authors:  Amanda D Buskirk; Steven P Templeton; Ajay P Nayak; Justin M Hettick; Brandon F Law; Brett J Green; Donald H Beezhold
Journal:  J Immunotoxicol       Date:  2013-08-06       Impact factor: 3.000

9.  Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8+ T cell responses against a HBV DNA vaccine in mice.

Authors:  Bing Wu; Qiang Zou; Yanxin Hu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

10.  Cimetidine synergizes with Praziquantel to enhance the immune response of HBV DNA vaccine via activating cytotoxic CD8(+) T cell.

Authors:  Xiaoping Xie; Shuang Geng; Hu Liu; Chaofan Li; Yuqin Yang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2014-03-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.